Mr
David
Akerman

Patent Attorney

Newcastle Office

Engineering

Telephone. +44(0) 191 205 8360
Email. [email protected]

Experience

Before qualifying as a patent attorney, David gained 20 years' IP management experience through in-house roles in textile and consumer-goods companies, making significant investment in innovation.

David’s IP experience includes undertaking freedom to operate projects, patent drafting, and developing IP strategies. He has also had involvement in IP due diligence in company and asset purchase projects.

In his in-house roles, David had significant involvement in contentious IP matters in Europe, USA and Japan, including patents, designs, trade dress, breach of confidence and know how.

After graduating from the University of Manchester, Institute of Science and Technology with an honours degree in Chemistry, David stayed on to undertake a PhD in Textile Chemistry. His research investigated the mechanism of oxidative bleaching of dyed cotton substrates during domestic laundering. The project was funded by industry and led to the publication of a patent application and three academic papers.

Qualifications

Patent Attorney

Chartered (UK)


BSC

Chemistry

PHD

Textile Chemistry

POSTGRADUATE DIPLOMA OR CERTIFICATE

PG Certificate in Intellectual Property

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.